<DOC>
	<DOC>NCT00744081</DOC>
	<brief_summary>The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.</brief_summary>
	<brief_title>Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Refractory AML after primary therapy First relapse after a safe previous diagnosis of de novo or secondary AML Age &gt; 18 years Serum bilirubin &lt; 2.0 mg/dl Serum creatinine &lt; 1.5 times the normal value or a creatinine clearance &gt; 60 ml/min ECG and heart echography prior to start of therapy without severe findings Overall condition &lt; 2 according to ECOG criteria Life expectancy &gt; 6 weeks Written informed consent by patients with full legal capacity Serious secondary disease (clinically relevant cardiac disease, chronic obstructive pulmonary disease, hepatic dysfunction, renal insufficiency) Active secondary neoplasia (exception: adequately treated basalioma or epidermoid cancer and cervical carcinoma) Known hypersensitivity to topoisomeraseI inhibitors Overall condition &gt; 2 according to ECOG criteria Pregnant/breast feeding women Serious intercurrent infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>